Business Responsibility and Sustainability Report
Section A: General Disclosures
I.	
Details of the listed entity: 
1.	 Corporate Identity Number (CIN) of the Listed Entity
L73100GJ2006PLC047837
2.	 Name of the Listed Entity
Sun Pharma Advanced Research Company Limited
3.	 Year of incorporation
2006
4.	 Registered office address
Plot No. 5&6/1, Savli G.I.D.C. Estate, Savli – Vadodara Highway, 
Manjusar - 391775, Vadodara, Gujarat, India
5.	 Corporate address
17/B, Mahal Industrial Estate, Off Mahakali Caves Road, Andheri 
(East), Mumbai - 400 093, Maharashtra
6.	 E-mail
secretarial@sparcmail.com
7.	 Telephone
+91 22 6645 5645
8.	 Website
https://sparc.life
9.	 Financial year for Reporting
2022-23
10.	Name and contact details (telephone, email address) 
of the person who may be contacted in case of any 
queries on the BRSR report
Dinesh Lahoti (Company Secretary)
Email – secretarial@sparcmail.com
Tel. No. +91 22 6645 5645 
11.	 Reporting boundary
Standalone Basis
12.	Name of the Stock Exchange(s) where shares are listed
BSE Limited and National Stock Exchange of India Limited
13.	Paid-up Capital (INR)
32,45,21,588
II.	
Products/services: 
14.	 Details of business activities (accounting for 90% of the turnover):
III.	 Operations: 
15.	 Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
Sr. 
No.
Description of Main Activity
Description of business 
activity
% Of turnover of the 
entity
1
Professional, Scientific and Technical
Scientific Research and 
Development
100
Sr. 
No.
Product/Service 
NIC Code 
% Of total Turnover 
contributed
1
Professional, Scientific and Technical
M5
100%
Location
Number of plants
Number of offices
Total
National
4*
0
4
International
0
1
1
	
* R&D facilities includes office areas
16. Number of locations where plants and/or operations/offices of the entity are situated
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
50
19.	 Participation/Inclusion/Representation of women
17.	 Markets served by the entity
	
a.	
Number of Locations
Total
(A)
No. and percentage of Females
No. (B)
% (B/A)
Board of Directors
6
1
17
Key Management Personnel
3
0
0
Locations
Number
National (No. of States)
3
International (No. of Countries)
2
	
b.	
What is the contribution of exports as a percentage of the total turnover of the entity?
	
	
55%
	
c.	
A brief on types of customers
	
	
Business to Business
IV.	 Employees: 
18.	 Details as at the end of Financial Year 
	
a.	
Employees and workers (including differently abled)
Sr. 
No.
Particulars
Total
Male
Female
(A)
No. (B)
% (B/A)
No. (C)
% (C/A)
Employee
1 
Permanent (D)
407
281
69
126
31
2 
Other than Permanent (E)
172
167
97
5
3
3 
Total employees (D + E)
579
448
77
131
23
Worker
4 
Permanent (F)
-
-
-
-
-
5 
Other than Permanent (G)
-
-
-
-
-
6 
Total workers (F + G)
-
-
-
-
-
Sr. 
No.
Particulars
Total
Male
Female
(A)
No. (B)
% (B/A)
No. (C)
% (C/A)
Differently Abled Employees
1
Permanent (D)
-
-
-
-
-
2
Other than Permanent (E)
-
-
-
-
-
3
Total employees (D + E)
-
-
-
-
-
Differently Abled Workers
4 
Permanent (F)
-
-
-
-
-
5 
Other than Permanent (G)
-
-
-
-
-
6 
Total workers (F + G)
-
-
-
-
-
	
b.	
Differently abled Employees and workers:
Statutory Reports
Business Responsibility and 
Sustainability Report
51
20.	 Turnover rate for permanent employees and workers (Disclose trends for the past 3 years)
V.	
Holding, Subsidiary and Associate Companies (including Joint Ventures)
21.	 Names of holding / subsidiary / associate companies / joint ventures as on 31st March, 2023
VI.	 Corporate Social Responsibility (CSR) Details
22.	
VII.	 Transparency and Disclosures Compliances
23.	 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business 
Conduct: 
Turnover Rate
FY 2022-23
FY 2021-22
FY 2020-21
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
13%
24%
16%
20%
15%
19%
12%
13%
12%
Permanent Workers
-
-
-
-
-
-
-
-
-
Sr. 
No.
Name of the holding / 
subsidiary / associate 
companies / joint 
ventures
Indicate whether holding/ 
Subsidiary/ Associate/ Joint 
Venture
% Of shares held by 
listed entity
Does the entity indicated at 
column A, participate in the 
Business Responsibility initiatives 
of the listed entity? (Yes/No)
Nil *
	
* Shanghvi Finance Private Limited (SFPL) was the Holding company of the Company till January 06, 2023. On January 06, 2023 the Company had allotted 
4,91,92,121 equity shares against the conversion of equal no. of warrants issued on preferential basis. Consequent to the said allotment, SFPL has ceased to be 
the Company’s Holding Company w.e.f. January 06, 2023 as its percentage shareholding along with its subsidiaries in the Company has reduced from 52.07% 
to 44.18%. The number of shares held by SFPL and its subsidiaries in the Company remain unchanged.
	
* In compliance with the requirements of Section 135 of the Act read with the Companies (Corporate Social Responsibility Policy) Rules, 2014, the Board 
of Directors has constituted a Corporate Social Responsibility Committee. Since the Company has incurred losses during the three immediately preceding 
financial years, the Company was not required to spend on CSR activities during the financial year ended March 31, 2023.
(i) Whether CSR is applicable as per section 135 of Companies Act, 2013
Yes *
(ii) Turnover (in Rs.)
2,38,78,00,734
(iii) Net worth (in Rs.)
5,12,77,46,757
Stakeholder 
group from whom 
complaint is 
received
Grievance 
Redressal 
Mechanism in 
Place (Yes/No)
FY 2022-23
FY 2021-22
(If yes, then 
provide 
web-link for 
grievance 
redress policy)
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Communities
Not applicable
-
-
-
-
-
-
Shareholders
Yes1
5
Nil
Nil
1
Nil
Nil
Investors (Other 
than shareholders)
Yes2
Nil
Nil
Nil
Nil
Nil
Nil
Employees and 
workers
Yes 
Nil
Nil
Nil
Nil
Nil
Nil
Customers
Not applicable
-
-
-
-
-
-
Value chain partners Yes3
Nil
Nil
Nil
Nil
Nil
Nil
	
1 The Company has a grievance redressal mechanism for shareholders. The Company has appointed Link Intime India Private Limited as the Share Transfer 
Registrars/ Agents. The Link Intime India Private Limited takes care of shareholders' enquiries/queries, requests and complaints. The Share Transfer 
Registrars/ Agents respond to enquiries/ queries, requests and complaints within the framework specified/ defined by SEBI. There is a dedicated email id to 
receive the grievances from shareholders- secretarial@sparcmail.com
	
2The Company has a common redressal mechanism for shareholders and investors, which has been captured in the row “Shareholders”
	
3 The grievance redressal mechanism for value chain partners is through email id, shared service helpdesk and Whistleblower mechanism.
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
52
24. Overview of the entity’s material responsible business conduct issues
	
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or 
mitigate the risk along-with its financial implications:
Sr. 
no.
Material 
issues 
identified
Indicate 
whether 
risk or 
opportunity
Rationale for identifying risk/
opportunity
In case of risk, 
approach to adapt or 
mitigate
Financial implications of the 
risk or opportunity (indicate 
positive or negative 
implications)
1
Data Integrity 
& Security
Risk and
Opportunity
Risk: Risk linked to technology 
directly impact the security and 
integrity of the system across the 
business operation. The criticality 
involved with the technology 
and cyber security needs to be 
assessed periodically to prevent 
breaches of data privacy from 
the aspects of confidential 
information of the Company.
Opportunity: A strong 
governance on the data integrity, 
technology, digitalization and 
innovation parameters of the 
Company enables the creation 
of a secure and impenetrable 
network while supporting 
pace and scale of business 
transactions across geographies.
Strengthened perimeter 
security, IT and 
monitoring systems, 
anti-virus and patch 
management while 
conducting trainings on 
cyber security to reduce 
risks arising from cyber 
security and data 
breaches.
Positive: Strong alignment 
of secure data integrity 
principles with the help of 
innovative technology and 
digitalisation initiatives within 
the Company’s business 
operations will ensure 
compliance of data security, 
privacy and prevent any loss 
of data.
Negative: Lack of a strong 
data integrity and security 
mechanism may lead to 
increase in number of data 
breaches and loss of valuable 
data.
2
Increasing 
probability 
of disruptive 
climate 
change events 
Risk
Risk: Risk of events occurring 
that may interrupt business 
operations or impair the ability 
of the Company to recover and 
maintain business operations in 
the event of disruptive climate 
change events.
Robust business 
continuity planning
Negative: Disruptive climate 
change events have the 
capability to interrupt 
business operations which 
can cause delays/ disruptions 
in research activities
3
Attracting
and retaining
talent
Risk and
Opportunity
Risk: Talent management 
parameters such as acquisition, 
retention and development are 
intrinsically linked to workforce 
welfare. Inability to meet with 
the workforce expectations may 
impact the Company’s retention 
rate and affect the Company’s  
business continuity due to the 
criticality of workforce as a part 
of the business growth plan. 
Opportunity: Company’s efforts 
towards workforce welfare and 
development directly conveys its 
resolute commitment towards 
the upliftment of the most 
integral asset.
1.	 Attracting and 
retaining talent 
through talent 
development 
programs along with 
compensation and 
other benefits to 
employees.
2.	 Formal succession 
planning programme 
for all leadership 
positions.
Positive: A strong workforce 
with high retention rate 
highlights the Company’s 
efforts towards creating a 
conducive work environment 
in addition to creating a 
positive approach towards 
workforce development 
Negative: Workforce being 
an integral component of the 
Company’s value creation 
strategy play a critical role 
in the business growth 
plan. Inability to meet the 
workforce expectations may 
result in adverse impacts on 
the workforce productivity 
and the company’s growth 
plan in a long run.
Statutory Reports
Business Responsibility and 
Sustainability Report
53
SECTION B: Management and Process Disclosures
The National Guidelines for Responsible Business Conduct (NGRBC) as prescribed by the Ministry of Corporate Affairs 
advocates nine principles referred as P1-P9 as given below:
P1
Businesses should conduct and govern themselves with integrity in a manner that is ethical, transparent and accountable
P2
Businesses should provide goods and services in a manner that is sustainable and safe
P3
Businesses should respect and promote the well-being of all employees, including those in their value chains
P4
Businesses should respect the interests of and be responsive towards all its stakeholders
P5 
Businesses should respect and promote human rights
P6
Businesses should respect, protect, and make efforts to restore the environment
P7 
Businesses when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and 
transparent
P8 
Businesses should promote inclusive growth and equitable development
P9 
Businesses should engage with and provide value to their consumers in a responsible manner
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and Management Processes
1.	 a.	 Whether your entity’s policy/policies cover each 
principle and its core elements of the NGRBCs. 
(Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
	
b.	 Has the policy been approved by the Board? (Yes/
No)
Yes, the Company has developed comprehensive policies covering these 
principles, some of the Policies have been approved by the Board as per 
relevant statutory requirements.
	
c.	 Web Link of the Policies, if available
https://sparc.life/policies-and-codes
2.	 Whether the entity has translated the policy into 
procedures. (Yes / No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
3.	 Do the enlisted policies extend to your value chain 
partners? (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
4.	 Name of the national and international codes/ 
certifications/ labels/ standards adopted by your 
entity and mapped to each principle.
P2 
•	 Certificate of Good Laboratory Practice (GLP) compliance by the 
National GLP Compliance Monitoring Authority, Government of India
•	 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical 
Practice E6(R2), version dated 9 November 2016
•	 ICH E3: Structure and Content of Clinical Study Reports, dated 30 
November 1995
•	 FDA 21 CFR Part 11: Electronic Records, Electronic Signatures
•	 New Drugs and Clinical Trial Rules, Mar 2019, India
5.	 Specific commitments, goals and targets set by the 
entity with defined timelines, if any.
To reduce water consumption by 10% by FY2028, considering baseline of 
FY2023
6.	 Performance of the entity against the specific 
commitments, goals, and targets along-with reasons 
in case the same are not met.
The Company has set environment targets in FY2022-23, hence the 
performance against set target will not be applicable for this reporting 
period.
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
54
Subject for Review
Indicate whether review was undertaken 
by Director / Committee of the Board/ Any 
other Committee
Frequency (Annually/ Half yearly/ 
Quarterly/ Any other – please specify)
P1
P2
P3
P4
P5
P6
P7
P8
P9
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance against above 
policies and follow up action
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Annual
Compliance with statutory 
requirements of relevance to the 
principles, and rectification of any 
non-compliances
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Annual
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Governance, Leadership, and Oversight
7.	 Statement by director responsible for the business 
responsibility report, highlighting ESG related 
challenges, targets, and achievements
“Sun Pharma Advanced Research Company (SPARC) is a clinical stage 
bio-pharmaceutical company focused on continuously improving 
standards of care for patients globally, through innovation in therapeutics 
and delivery. Our accountability to patients we seek to serve and investors 
who enable us and our commitment to sustainable human progress are 
key components of our identity – A responsible innovator inspired by life’s 
amazing ability to learn, evolve and survive. 
SPARC is committed to building a sustainable business and embedding 
ESG parameters into the business growth model. Our ESG related 
challenges, targets and achievements are mentioned at various parts 
within this report.”
Sudhir V. Valia
Non-Executive Director
8.	 Details of the highest authority responsible for 
implementation and oversight of the Business 
Responsibility policy (ies).
Name: Anil Raghavan
Designation: Chief Executive Officer
9.	 Does the entity have a specified Committee of the 
Board/ Director responsible for decision making 
on sustainability related issues? (Yes / No). If yes, 
provide details.
Yes, Sudhir V. Valia, Non-Executive Director. Further, Mr. Anil Raghavan, 
Chief Executive Officer of the Company oversees the Business 
Responsibility and Sustainability initiatives of the Company.
11.	Has the entity carried out independent 
assessment/ evaluation of the working of its 
policies by an external agency? (Yes/No). 
	
If yes, provide name of the agency
P1
P2
P3
P4
P5
P6
P7
P8
P9
No. The Company internally reviews the working of the above-mentioned 
policies.
10.	 Details of Review of NGRBCs by the Company:
Statutory Reports
Business Responsibility and 
Sustainability Report
55
12.	 If answer to question (1) above is “No” i.e., not all Principles are covered by a policy, reasons to be stated:
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the principles material to 
its business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position 
to formulate and implement the policies on specified 
principles (Yes/No)
The entity does not have the financial or/human and 
technical resources available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/
No)
Any other reason (please specify)
SECTION C: Principle wise Performance Disclosure
Ethics and Integrity
  Principle 1:	
Businesses should conduct and govern themselves with integrity, and in a manner that is 
Ethical, Transparent and Accountable
Essential Indicators
1.	
Percentage coverage by training and awareness programs on any of the principles during the financial year 2022- 23:
2.	
Details of fines / penalties /punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity 
or by directors / KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial year 2022- 23:
Segment
Total number of training and 
awareness programs held
Topics/ principles covered 
under the training and its 
impacts
Percentage of persons in 
respective category covered 
by the awareness programs
Board of Directors
5
Principle 1,2,3,4,5,6,7,8,9
100%
Key Managerial Personnel
5
Principle 1,2,3,4,5,6,7,8,9
100%
Employees other than Board of 
Directors and KMPs
4
Principle 1,2,3,4,5,6,7,8,9
100%
Workers
NA
NA
NA
Monetary
NGRBC 
Principle
Name of the Regulatory/ 
Enforcement agencies/ 
Judicial institution
Amount 
(In INR)
Brief of the 
Case
Has an appeal 
been preferred?
(Yes / No)
Penalty/ Fine
-
-
-
-
-
Settlement
-
-
-
-
-
Compounding Fee
-
-
-
-
-
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
56
3.	
Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-
monetary action has been appealed.
6.	
Details of complaints with regard to conflict of interest:
FY 2022-23
FY 2021-22
Board of Directors
-
-
Key Managerial Personnel
-
-
Employees other than Board of Directors and KMPs
-
-
Workers
NA
NA
FY 2022-23
FY 2021-22 
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues of 
Conflict of Interest of the directors
-
NA
-
NA
Number of complaints received in relation to issues of 
Conflict of Interest of the KMPs
-
NA
-
NA
Case Details
Name of the regulatory/ enforcement agencies/ judicial institutions
 Not applicable 
Non-Monetary
NGRBC Principle
Name of the Regulatory/ 
Enforcement agencies/ 
Judicial institution
Brief of the Case
Has an appeal 
been preferred?
(Yes / No)
Imprisonment
-
-
-
-
Punishment
-
-
-
-
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a 
weblink to the policy.
	
Yes, the Anti-bribery policy in the Company’s Global Code of Conduct outlines the Company’s commitment to conduct business 
with integrity. The Company abides by all the applicable anti-bribery laws including US Foreign Corrupt Practices Act (FCPA). The 
Anti-bribery policy as part of the Global Code of Conduct is applicable to all the employees (whether permanent, temporary or 
on contract, direct or through contractor, retainer or full-time consultant), and members of the Board of Directors of the Company 
(“Personnel”). The Company expects its business partners, including suppliers, service providers, agents, channel partners 
(dealers, distributors and others) to adhere to the principles of the code. Weblink: https://sparc.life/policies-and-codes
5.	
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement 
agency for the charges of bribery/ corruption:
7.	
Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ 
law enforcement agencies/ judicial institution on cases of corruption and conflicts of interest.
	
Not Applicable
Statutory Reports
Business Responsibility and 
Sustainability Report
57
Leadership Indicators
Essential indicators
1.	
Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/No) 
If yes, provide details of the same.
	
Yes, the Company’s Global Code of Conduct expects all its Personnel to refrain from engaging in any activity or having a personal 
interest that presents a conflict of interest. Further, the Company outlines that Personnel of the Company shall not exploit any 
information discovered through their position in the Company, for their own personal gain.
Sustainable Business
  Principle 2:	
Businesses should provide goods and services in a manner that is sustainable and safe
1.	
Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the environmental and 
social impacts of product and processes to total R&D and capex investments made by the entity, respectively.
FY 2022-23
FY 2021-22
Details of improvements 
in environmental and 
social impacts
R&D
0%
0%
NA
Capex
0%
0%
NA
2.a.	Does the entity have procedures 
in place for sustainable sourcing? 
(Yes/No)
Yes. The Company endeavours to implement responsible procurement practices. As 
a measure of enhancing its impact on the environment and society, the Company 
encourages local sourcing enabling the reduction in costs, currency risks and 
environmental footprint of the transportation services
2.b.	If yes, what percentage of inputs 
were sourced sustainably?
100% of inputs sourced from critical suppliers is sourced sustainably
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for 
(a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste. 
	
Not applicable as the company does not manufacture any products
4.	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). 
	
•	
If yes whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution 
Control Boards? 
	
•	
If not provide steps taken to address the same.
	
Not applicable
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
58
Essential Indicators
Leadership Indicators
Employee Wellbeing
  Principle 3:	
Businesses should respect and promote the well-being of all employees, including those in 
their value chains
1.	
Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing industry) 
or providing services (for service industry).
	
The Company does not reuse any input material considering the nature of services
2.	
Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely 
disposed, as per the following format:
	
Not applicable
3.	
Reclaimed products and their packaging materials (as percentage of products sold) for each product category.
	
Not applicable
1.	
a.	
Details of measures for the well-being of employees:
	
b.	
Details of measures for the well-being of workers:
% Of employees covered by
Category
Total 
(A)
Health insurance
Accident 
insurance
Maternity 
benefits
Paternity 
Benefits
Day Care 
facilities
Number 
(B)
% 
(B/A)
Number 
(C)
% 
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent
Male
281
281
100
281
100
NA
NA
281
100
281
100
Female
126
126
100
126
100
126
100
NA
NA
126
100
Total
407
407
100
407
100
126
31
281
69
407
100
Other Than Permanent
Male
167
162
97
162
97
NA
NA
162
97
0
0
Female
5
1
20
1
20
1
20
NA
NA
0
0
Total
172
163
95
163
95
1
1
162
94
0
0
% Of workers covered by
Category
Total 
(A)
Health insurance
Accident 
insurance
Maternity 
benefits
Paternity 
Benefits
Day Care 
facilities
Number 
(B)
% 
(B/A)
Number 
(C)
% 
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent
Male
-
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
-
Total
-
-
-
-
-
-
-
-
-
-
-
Other Than Permanent
Male
-
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
-
Total
-
-
-
-
-
-
-
-
-
-
-
Statutory Reports
Business Responsibility and 
Sustainability Report
59
2.	
Details of retirement benefits, for FY 2022-23 and FY 2021-22
Benefits
FY 2022-23
FY 2021-22
No. of 
employees 
covered as a % 
of total
employees
No. of workers 
covered as a % 
of total
workers
Deducted and 
deposited 
with the 
authority
(Y/N/N.A.)
No. of 
employees 
covered as a % 
of total
employees
No. of workers 
covered as a % 
of total
workers
Deducted and 
deposited 
with the 
authority
(Y/N/N.A.)
PF
100
-
Y
100
-
Y
Gratuity
100
-
Y
100
-
Y
ESI
0.48
-
Y
0.50
-
Y
3.	
Accessibility of workplaces
5.	
Return to work and Retention rates of permanent employees and workers that took parental leave.
6.	
Is there a mechanism available to receive and redress grievances for the following categories of employees and worker? If 
yes, give details of the mechanism in brief.
4.	 Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 
2016? (Yes/ No) 
Yes
If so, provide a web link to the policy. 
NA
Are the premises/ offices of the entity accessible to differently 
abled employees and workers as per the requirements of the 
Rights of Persons with Disabilities Act 2016? (Yes/ No) 
Yes, As per the requirements of the Rights of Persons with 
Disabilities, the Company’s offices have ramps, elevators 
and infrastructure for differently abled individuals.
Gender
Permanent Employees
Permanent Workers
Return to work 
rate (%)
Retention rate 
(%)
Return to work 
rate (%)
Retention rate 
(%)
Male
100
100
-
-
Female
100
100
-
-
Total
100
100
-
-
Yes/No
(If yes, then give details of the mechanism in brief)
Permanent employees
Yes. The Company has online platform, email and other informal channels of 
communication for grievance redressal
Other than Permanent employees
No
Permanent workers
Not Applicable
Other than Permanent workers
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
60
Category
FY 2022-23
FY 2021-22
Total employees 
/ workers in 
respective 
category
(A)
No. of employees / 
workers in respective 
category, who are part of 
association(s) or Union 
(B)
% 
(B/A)
Total employees 
/ workers in 
respective 
category
(C)
No. of employees / 
workers in respective 
category, who are part of 
association(s) or Union
(D)
% 
(D/C)
Total Permanent 
Employees
407
-
0
403
-
0
Male
281
-
0
266
-
0
Female
126
-
0
137
-
0
Total Permanent 
Workers
-
-
-
-
-
-
Male
-
-
-
-
-
-
Female
-
-
-
-
-
-
Benefits
FY 2022-23 
FY 2021-22
Total  (A)
No. (B)
%(B/A)
Total (C)
No. (D) 
% (D/C)
Employee
Male
281
281
100
266
266
100
Female
126
126
100
137
137
100
Total
407
407
100
403
403
100
Workers
Male
-
-
-
-
-
-
Female
-
-
-
-
-
-
Total
-
-
-
-
-
-
7.	
Membership of employees and worker in association(s) or Unions recognized by the listed entity:
8.	
Details of training given to employees and workers:
9.	
Details of performance and career development reviews of employees and worker:
10.	 Health and Safety Management System:
a)	Whether an occupational health and safety management 
system has been implemented by the entity? (Yes/ No). 
Yes
	 If yes, the coverage of such system?
100%
b)	What are the processes used to identify work-related hazards and 
assess risks on a routine and non-routine basis by the entity?
The Company conducts EHS training by internal & external 
trainers and audits for the implementation of best safety practices
c)	Whether you have processes for workers to report the work-
related hazards and to remove themselves from such risks. (Y/N) Yes
d)	Do the employees/ worker of the entity have access to non-
occupational medical and healthcare services? (Yes/ No)
Yes
Category
FY 2022-23 
FY 2021-22
Total
(A)
On Health Safety
On Skill 
Upgradation
Total
(D)
On Health Safety
On Skill 
Upgradation
No. (B)
 % (B/A)
No. (C)
 % (C/A)
No. (E)
 % (E/D)
No. (F)
 % (F/D)
Employees
Male
281
281
100
281
100
266
266
100
266
100
Female
126
126
100
126
100
137
137
100
137
100
Total
407
407
100
407
100
403
403
100
403
100
Workers
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Total
-
-
-
-
-
-
-
-
-
-
Statutory Reports
Business Responsibility and 
Sustainability Report
61
11.	 Details of safety related incidents:
13.	 Number of Complaints on the following made by employees and workers:
14.	 Assessments for the year:
12.	 Describe the measures taken by the entity to ensure a safe and healthy workplace.
	
The Company undertakes periodic internal audits to assess the safety practices as per relevant regulations. The safety incidents 
and hazards are analyzed to determine the root cause, subsequently corrective action plans are laid out to prevent the occurrence 
of similar incidents in the future. As part of the EHS management system, the company provides safety trainings and safety drill 
practices to all employees.
Safety Incident/Number
Category
FY 2022-23
FY 2021-22
Lost Time Injury Frequency Rate (LTIFR)
Employees
Nil
Nil
Workers
-
-
Total recordable work-related injuries
Employees
Nil
Nil
Workers
-
-
Number of fatalities
Employees
Nil
Nil
Workers
-
-
High consequence work-related injury or ill-health (excluding 
fatalities) 
Employees
Nil
Nil
Workers
-
-
FY 2022-23
FY 2021-22
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Working 
Conditions
-
-
-
-
-
-
Health & Safety
-
-
-
-
-
-
% Of your plants and offices that were assessed. (by entity or statutory authorities or third parties)
Health and safety practices
100
Working Conditions
100
15.	 Provide details of any corrective action taken or underway 
to address safety related incidents (if any) and on 
significant risks / concerns arising from assessments of 
health & safety practices and working conditions. 
No safety incident occurred
A) Employees
Yes
B) Workers
-
Leadership Indicators
1.	
Does the entity extend any life insurance or any compensatory package in the event of death of: (Y/N)?
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
62
2.	
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by the 
value chain partners.
3.	
Provide the number of employees / workers having suffered high consequence work-related injury / ill-health / fatalities 
(as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable employment or 
whose family members have been placed in suitable employment:
4.	
Does the entity provide transition assistance programs to facilitate continued employability and the management of career 
endings resulting from retirement or termination of employment? (Yes/ No)
	
Yes, the Company periodically conducts skill-upgradation training programs for all its employees.
	
The Company requires its value chain partners to abide by the principles of the Company’s Supplier Code of Conduct and 
implement responsible business conduct principles in its operating practices
Total no. of affected employees/ 
workers
No.  of employees/workers that are rehabilitated 
and placed in suitable employment or whose 
family members have been placed in suitable 
Employment
FY 2022-23
FY 2021-22
FY 2022-23
FY 2021-22 
Employees
0
0
NA
NA
Workers
-
-
-
-
Essential Indicators
Stakeholder inclusiveness
  Principle 4:	
Businesses should respect the interests of and be responsive to all its stakeholders
1.	
Describe the processes for identifying key stakeholder groups of the entity.
	
The stakeholder groups are identified as part of the stakeholder engagement mechanism, built on the principles of inclusivity, 
accountability, and responsibility. The Company identifies key stakeholder groups based on those groups who are impacted as 
well as  those who have a major influence on the business decisions.
2.	
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder group.
Stakeholder
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group. (Yes/
No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement,
Community Meetings,
Notice Board, Website), 
Other
Frequency of 
engagement 
(Annually/ Half
yearly/ Quarterly 
/ others – please 
specify)
Purpose and scope of engagement 
including key topics and concerns 
raised during such engagement
Investor
No
•	
Annual/ quarterly reports 
and earning calls
•	
Attending investor 
conferences
•	
Issuing specific event 
based press releases
•	
Investor presentations
Quarterly/ Need 
Based
Investors form an integral part of the 
stakeholder group, influencing the 
decisions of the Company.
The key areas of interest for the investors 
are:
•	
Corporate governance
•	
Regulatory compliance
•	
Overall Company performance
Statutory Reports
Business Responsibility and 
Sustainability Report
63
Stakeholder
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group. (Yes/
No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement,
Community Meetings,
Notice Board, Website), 
Other
Frequency of 
engagement 
(Annually/ Half
yearly/ Quarterly 
/ others – please 
specify)
Purpose and scope of engagement 
including key topics and concerns 
raised during such engagement
Regulator 
No
•	
In person meetings
•	
E-mail
Need-based
Transparent communication with the 
regulators is critical from a compliance 
perspective
Vendor
No
•	
Vendor meets
•	
Virtual modes such as 
telephone, email, etc.
Ongoing
Responsible supply chain practices 
are critically important for ensuring the 
business continuity in a sustainable 
manner. The key areas of interest for the 
suppliers are:
•	
Timely payments
•	
Collaboration
Customer
No
•	
In-person meetings
•	
E-mail
Ongoing
Customers form a vital part of the 
Company’s stakeholder engagement 
group to ensure quality services
Employee
No
•	
Employee focused web-
portal
•	
E-mail
•	
Employee engagement 
surveys
•	
Town-halls
Ongoing
Employee wellbeing and satisfaction is 
an integral part of the Company’s growth 
model. Employee engagement through 
various means of communication provides 
an insight into the key action 
areas for employee wellbeing and growth. 
The key areas of interest for employees 
are:
•	
Training, professional growth and 
development
•	
Well-being initiatives
•	
Employee recognition
•	
Fair remuneration
•	
Work-life balance
Leadership Indicators
1.	
Provide the processes for consultation between stakeholders and the Board on economic, environmental and social topics 
or if consultation is delegated, how is feedback from such consultations provided to the Board.
	
The identified material issues were presented to the Board for their feedback and guidance on the sustainable growth model of 
the Company
2a.	Whether stakeholder consultation is used to support the 
identification and management of environmental and 
social topics (Yes / No). 
Yes. The identified issues are mapped with relevant risks 
as part of the risk management process. The Company 
subsequently develops mitigation plans for the identified 
issues.
2b.	If so, provide details of instances as to how the inputs 
received from stakeholders on these topics were 
incorporated into policies and activities of the entity.
3.	
Provide details of instances of engagement with and actions taken to address the concerns of vulnerable/ marginalized 
stakeholder groups.
	
Not applicable
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
64
Essential Indicators
Human Rights
  Principle 5:	
Businesses should respect and promote human rights
1.	
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity:
2.	
Details of minimum wages paid to employees and workers:
Category
FY 2022-23
FY 2021-22
Total (A)
No. of employees / 
workers covered (B)
% (B/A)
Total (C)
No. of employees / 
workers covered (D)
% (D/C)
Employees
Permanent
407
407
100
403
403
100
Other than permanent
172
172
100
148
148
100
Total Employees
579
579
100
551
551
100
Workers
Permanent
-
-
-
-
-
-
Other than permanent
-
-
-
-
-
-
Total Workers
-
-
-
-
-
-
Category
FY 2022-23 
FY 2021-22
Total
(A)
Equal to Minimum 
Wage
More than 
Minimum Wage
Total
(D)
Equal to Minimum 
Wage
More than 
Minimum Wage
No. (B)
 % (B/A)
No. (C)
 % (C/A)
No. (E)
 % (E/D)
No. (F)
 % (F/D)
Employees
Permanent
407
0
0
407
100
403
0
0
403
100
Male
281
0
0
281
100
266
0
0
266
100
Female
126
0
0
126
100
137
0
0
137
100
Other than 
permanent
172
158
92
14
8
148
140
95
8
5
Male
167
157
94
10
6
146
139
95
7
5
Female
5
1
20
4
80
2
1
50
1
50
Workers
Permanent
-
-
-
-
-
-
-
-
-
-
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Other than 
permanent
-
-
-
-
-
-
-
-
-
-
Male
-
-
-
-
-
-
-
-
-
-
Female
-
-
-
-
-
-
-
-
-
-
Statutory Reports
Business Responsibility and 
Sustainability Report
65
3.	
Details of remuneration/salary/wages:
Gender
Male
Female
Number
Median 
remuneration/ 
salary/ wages of 
respective category
Number
Median 
remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD) *
5
NA *
1
NA *
Key Managerial Personnel (KMP)
3
1,73,66,741 #
Nil
NA
Employees other than BoD and KMP
278
19,23,330
126
10,74,576
Workers
-
-
-
-
	
*Directors are only paid sitting fees of Rs. 30,000 per meeting attended
	
#as per Form 16 
4.	 Do you have a focal point (Individual/ Committee) responsible 
for addressing human rights impacts or issues caused or 
contributed to by the business? (Yes/No)
Yes, the Head of Human Resource department of the 
Company is responsible for addressing human rights 
impact or issues
5.	
Describe the internal mechanisms in place to redress grievances related to human rights issues.
	
The Company ‘Ask HR’ / ‘RAY’ platform, email and other informal channels of communication form part of the internal mechanism 
for grievance redressal of human rights issues. The process is in place to address grievances   through the open channels of 
communication and the Ombudsman channel as per the Whistleblower Policy. The Ombudsman ensures the confidentiality of the 
complaints and grievances received through email.
6.	
Number of complaints on the following made by employees and workers:
FY 2022-23
FY 2021-22
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Filed during 
the year
Pending 
resolution at the 
end of year
Remarks
Sexual Harassment
0
0
-
0
0
-
Discrimination at 
workplace
0
0
-
0
0
-
Child Labour
0
0
-
0
0
-
Forced/ 
Involuntary Labour 
0
0
-
0
0
-
Wages
0
0
-
0
0
-
Other human rights 
related issues
0
0
-
0
0
-
7.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
	
As per the Whistleblower Policy, the Company ensures protection of the complainant. The investigation of the complaints is done 
strictly in a confidential manner ensuring the protection of the complainant against any retaliation.
	
The Company provides necessary safeguards to all Whistle Blowers for making Protected Disclosures in good faith, in all the areas 
covered under the Global Code of Conduct .
	
For the cases pertaining to sexual harassment, the Company’s policy on prevention, prohibition and redressal of sexual harassment 
at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) 
Act, 2013 and the Rules made thereunder ensures strict confidentiality of the investigation procedure and protection of the identity 
of the complainant.
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
66
9.	
Assessments for the year:
10.	 Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the 
assessments at Question 9 above.
	
No significant risks or concerns observed.
8.	 Do human rights requirements form part of your business 
agreements and contracts? (Yes/No)
Yes. They form an integral part of business agreements 
and contracts.
% Of your plants and offices that were assessed (by entity or statutory authorities 
or third parties)
Sexual harassment 
100
Discrimination at workplace
100
Child labour
100
Forced Labour/ Involuntary Labour
100
Wages
100
Other human rights related issues
100
Leadership Indicators
1.	
Details of a business process being modified / introduced as a result of addressing human rights grievances/complaints.
	
NA
2.	
Details of the scope and coverage of any Human rights due diligence conducted.
	
None. 
3.	
Is the premise/office of the entity accessible to differently abled visitors as per the requirements of the Rights of Persons 
with Disabilities Act 2016?
	
Yes.
4.	
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such 
partners) that were assessed
Sexual harassment 
0
Discrimination at workplace
0
Child labour
0
Forced Labour/ Involuntary Labour
0
Wages
0
Other human rights related issues
0
5.	
Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the 
assessments at Question 4 above.
	
NA
Statutory Reports
Business Responsibility and 
Sustainability Report
67
Essential Indicators
Environment 
  Principle 6:	
Businesses should respect and make efforts to protect and restore the environment
1.	
Details of total energy consumption (in Joules or multiples) and energy intensity:
Parameter
FY 2022–23
FY 2021–22
Total electricity consumption (A)
18,417 GJ
14,950 GJ
Total fuel consumption (B)
350 GJ
409 GJ
Energy consumption through other sources – Steam (C)
93 GJ
93 GJ
Total energy consumption (A+B+C)
18,860 GJ
15,453 GJ
Energy intensity per rupee of turnover (Total energy consumption/ turnover in Mn 
rupees)
8
11
Parameter
FY 2022–23
FY 2021–22
Water Withdrawn by the source (KL)
i) Surface Water
0
0
ii) Ground Water
4,491
4,306
iii) 3rd Party Water
27,004
18,837
iv) Seawater/desalinated water
0
0
v) Others
0
0
Total Vol of Water Withdrawn (i + ii + iii + iv + V) 
31,495
23,143
Total Vol of Water Consumed (KL)
31,495
23,143
Water intensity per rupee of turnover. (Water consumed in KL/Mn Rupee of turnover)
13
17
2.	
Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and 
Trade (PAT) Scheme of the Government of India? (Yes/ No). If yes, disclose whether targets set under the PAT scheme have 
been achieved. In case targets have not been achieved provide the remedial action taken if any.
	
No.
3.	
Provide details of the following disclosures related to water:
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency.
	
Yes. By M/s. Eco Care Solutions and Envirocare Labs Private Limited
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. 
	
No
4.	 Has the entity implemented a mechanism for Zero Liquid 
Discharge? (Yes/ No)
Yes
If yes, Provide details of its coverage and implementation.
The Company has effluent treatment plant to treat the 
waste water which then is used  for gardening and  
cleaning.
5.	
Please provide details of air emissions (other than GHG emissions) by the entity:
Parameter
Please specify unit of 
measurement (UoM)
FY 2022–23
FY 2021–22
NOx
Kgs
185
179
Sox
Kgs
106
112
Particulate Matter (PM)
Kgs
159
160
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
68
6.	
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity:
Parameter
Unit
FY 2022–23
FY 2021–22
Total Scope 1 emissions 
Metric tonnes of CO2 equivalent
0
0
Total Scope 2 emissions
Metric tonnes of CO2 equivalent
0
0
Total Scope 1 and Scope 2 emissions per rupee of 
turnover
NA
0
0
7.	
Does the entity have any project related to reducing Green House Gas emission? 
	
If yes, then provide details. 
	
No
8.	
Provide details related to waste management by the entity:
Total Waste generated (in metric tonnes)
Parameter
FY 2022-23
FY 2021-22
Plastic waste (A)
0
0
E-waste (B)
0
0
Bio-medical waste (C)
13
8
Construction and Demolition waste (D)
0
0
Battery waste (E)
0
0
Radioactive waste (F)
0
0
Other Hazardous waste (G) 
12
10
Other Non-hazardous waste generated (H)
35
20
Total (A+B+C+D+E+F+G+H)
60
37
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations 
(in metric tonnes) 
Parameter
FY 2022-23
FY 2021-22
(i)	 Recycled
0
0
(ii)	 Re-used
0
0
(iii)	Other recovery operations
0
0
Total
0
0
For each category of waste generated, total waste disposed by nature of disposal method  (in metric tonnes)
Parameter
FY 2022-23
FY 2021-22
(i)	 Incineration
11
10
(ii)	 Landfilling
0
0
(iii)	Other disposal operations
48
27
Total
60
37
9.	
Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your 
company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to 
manage such wastes.
	
The Company has adopted a waste management plan with a comprehensive approach towards waste minimization, segregation 
and safe disposal. The Company sends the hazardous waste like spent oil to recycling units. 
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. 
	
No
Statutory Reports
Business Responsibility and 
Sustainability Report
69
10.	 If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, 
biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals 
/ clearances are required, please specify details:
	
Not applicable
11.	 Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current 
financial year:
	
Not applicable
12.	 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and 
rules thereunder (Y/N). If not, provide details of all such non-compliances:
	
Yes
Leadership Indicators
1.	
Provide break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable sources:
Parameter
Parameter
FY 2022–23
FY 2021–22
From Renewable Sources
Total electricity consumption (A) (Wind, Solar and Power Purchase Agreements (PPAs))
0 GJ
0 GJ
Total fuel consumption (B) (Biomass)
0 GJ
0 GJ
Energy consumption through other sources (C) (Steam)
93 GJ
93 GJ
Total energy consumed from renewable sources (A+B+C)
93 GJ
93 GJ
From Non-Renewable Sources
Total electricity consumption (D) (Grid electricity)
18,417 GJ
14,950 GJ
Total fuel consumption (E)
(Diesel, Petrol, High Speed Diesel, Compressed Natural Gas, Liquified Petroleum Gas, 
Coal, Furnace Oil)
350 GJ
409 GJ
Energy consumption through other sources (F)
0 GJ
0 GJ
Total energy consumed from non-renewable sources (D+E+F)
18,767 GJ
15,359 GJ
2.	
Provide the following details related to water discharged:
Parameter
FY 2022-23
FY 2021-22
Water discharge by destination and level of treatment (KL)
(i)	 To Surface Water
0
0
	
-  No treatment
0
0
	
- With treatment 
0
0
(ii)	To Groundwater
0
0
	
- No treatment
0
0
	
- With treatment 
0
0
(iii)	To Seawater
0
0
	
- No treatment
0
0
	
- With treatment
0
0
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency. 
	
No
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
70
Parameter
FY 2022-23
FY 2021-22
(iv)	Sent to third parties (discharged to common drain)
2787
2549
	
- No treatment
0
0
	 - With treatment (Post primary, secondary and tertiary treatment, treated water is 
drained in common sewer)
2787
2549
(v)	 Others (Reused)
4942
3431
	
- No treatment
0
0
	 - With treatment (Post primary, secondary and tertiary treatment, treated water is 
reused)
4942
3431
Total Water discharged (KL)
7729
5980
Parameter
Unit
FY 2022-23
FY 2021-22
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, 
N2O, HFCs, PFCs, SF6, NF3, if available)
Metric Tonnes of 
CO2 equivalent
0
0
Total Scope 3 emissions per Rupee of turnover
0
0
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If 
yes, name of the external agency.
	
Yes. By M/s. Eco Care Solutions and Envirocare Labs Private Limited
3.	
Water withdrawal, consumption, and discharge in areas of water stress (in kiloliters):
	
Not applicable
4.	
Please provide details of total Scope 3 emissions & its intensity in the following format:
6.	
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource 
efficiency, or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as 
well as outcome of such initiatives:
	
No
7.	
Does the entity have a business continuity and disaster management plan? Give details in 100 words/ web link.
	
Yes, the Company has a business continuity and disaster management plan in place. This business continuity plan enables the 
Company to adapt in situations arising from any natural calamity or an unprecedented event which may disrupt the business 
operations. The Company continuously enhances its existing plan by incorporating interferences and observations from 
disruptions faced in the unprecedented situations such as the pandemic. Further, the Company’s risk management plan enables 
the minimisation of disaster-linked losses, by assessing the potential for major disruption with its consequent risks to the business, 
and by providing the appropriate mitigation action plans.
8.	
Disclose any significant adverse impact to the environment arising from the value chain of the entity. What mitigation or 
adaptation measures have been taken by the entity in this regard?
	
Not applicable
9.	 Percentage of value chain partners (by value of business 
done with such partners) that were assessed for 
environmental impacts.
Nil
5.	
With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details 
of significant direct & indirect impact of the entity on biodiversity in such areas along with prevention and remediation 
activities. 
	
Not Applicable
Statutory Reports
Business Responsibility and 
Sustainability Report
71
Essential Indicators
Essential Indicators
Responsible Public Advocacy  
Community upliftment  
  Principle 7:	
Businesses, when engaging in influencing public and regulatory policy, should do so in a 
manner that is responsible and transparent
  Principle 8:	
Businesses should promote inclusive growth and equitable development
1.a	 Number of affiliations with trade and industry chambers/ associations.
	
One
1.b	 List the top 10 trade and industry chambers/ associations (determined based on the total members of such body) the entity 
is a member of/ affiliated to.
Sr. No.
Name of the trade and industry chambers/ 
associations
Reach of trade and industry chambers/ 
associations (State/National)
1
IMC Chamber of Commerce and Industry
National
2.	
Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, 
based on adverse orders from regulatory authorities.
	
Not applicable
1.	
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current 
financial year.
	
NA
2.	
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your 
entity:
	
NA
3.	
Describe the mechanisms to receive and redress grievances of the community.
	
NA
4.	
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
Parameter
FY 2022-23
FY 2021-22
Directly sourced from MSMEs/ small producers
8%
10%
Sourced directly from within the district and neighboring districts
-
-
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
72
Essential Indicators
Leadership Indicators
Consumer Wellbeing 
  Principle 9:	
Businesses should engage with and provide value to their customers and consumers in a 
responsible manner
1.	
Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments 
(Reference: Question 1 of Essential Indicators above):
	
NA
2.	
Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as 
identified by government bodies:
	
Not Applicable
3.a.	Do you have a preferential procurement policy where you 
give preference to purchase from suppliers comprising 
marginalized /vulnerable groups? (Yes/No)
No
3.b	From which marginalized /vulnerable groups do you 
procure?
NA
3.c	What percentage of total procurement (by value) does it 
constitute?
NA
4.	
Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the current 
financial year), based on traditional knowledge:
	
Nil
5.	
Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes 
wherein usage of traditional knowledge is involved
	
Not applicable
6.	
Details of beneficiaries of CSR Projects:
CSR Projects
No. of persons benefitted from CSR 
Projects
% Of beneficiaries from vulnerable and 
marginalized groups
Not Applicable
1.	
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
	
The Company is engaged in research and development activities. It does not provide services directly to consumers. Hence not 
applicable.
2.	
Turnover of products and/ services as a percentage of turnover from all products/ services that carry information about 
Environmental product and social parameters relevant to the Product, Safe and responsible usage and Recycling and/or 
safe disposal:
	
Not applicable
Statutory Reports
Business Responsibility and 
Sustainability Report
73
3.	
Number of consumer complaints in respect of the following:
4.	
Details of instances of product recalls on account of safety issues:
	
Not applicable
FY 2022–23
Remark
FY 2021–22
Remark
Received 
during the year
Pending 
resolution at 
end of year
Received 
during the year
Pending 
resolution at 
end of year
Data privacy
-
-
-
-
-
-
Advertising
-
-
-
-
-
-
Cyber-security
-
-
-
-
-
-
Delivery of essential services
-
-
-
-
-
-
Restrictive Trade Practices
-
-
-
-
-
-
Unfair Trade Practices
-
-
-
-
-
-
Others
-
-
-
-
-
-
5.	 Does the entity have a framework/ policy on cyber 
security and risks related to data privacy? (Yes/No) 
No
If available, provide a web-link of the policy.
a.	 Number of instances of data breaches along-with 
impact
There was one data breach identified during the year, outside the 
organization. There were no complaints received concerning the 
breaches of customer privacy. 
b.	 Percentage of data breaches involving personally 
identifiable information of customers
Nil
4.a Does the entity display product information on the product 
over and above what is mandated as per local laws? (Yes/
No/Not Applicable)
Not applicable
4.b If yes, provide details in brief.
Not applicable
4.c Did your entity carry out any survey with regard to 
consumer satisfaction relating to the major products / 
services of the entity, significant locations of operation of 
the entity or the entity as a whole? (Yes/No)
No
6.	
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential 
services; cyber security and data privacy of customers; re occurrence of instances of product recalls; penalty / action 
taken by regulatory authorities on safety of products / services. 
	
Not applicable
Leadership Indicators
1.	
Channels / platforms where information on products and services of the entity can be accessed (provide web link if 
available).
	
https://sparc.life
2.	
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
	
Not Applicable
3.	
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
	
Not Applicable
5.	
Provide the following information relating to data breaches:
Annual Report 2022-23
Sun Pharma Advanced Research Company Ltd.
74
